PsychedelicNewsBreaks

ThursdayFeb 10, 2022 1:50 pm

PsychedelicNewsBreaks – Microdose Psychedelic to Host February Molecular Masterclass: The LSD Conference

Microdose Psychedelic Insights, a cutting-edge media company focused on promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, announced that it will be hosting the Molecular Masterclass: LSD Conference next week. Microdose is hosting the event, scheduled for Feb. 17, 2022, in partnership with MindBio Therapeutics. The all-virtual conference is designed to offer a scientific deep dive into the dynamic field of LSD microdosing exploring the potential of LSD at the intersection of drug development and safety, clinical care and applications, law and regulation, business and markets, science and research, and…

Continue Reading

WednesdayFeb 09, 2022 2:26 pm

PsychedelicNewsBreaks – Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Committed to Bringing Science-Backed Health Benefits to All, Reframing Psychedelic Conversation

Delic Holdings (CSE: DELC) (OTCQB: DELCF), the leading psychedelic wellness platform, has sought to capitalize on the ongoing transformation within the mental health sector. The company is positioning itself as the United States’ leading psychedelic wellness platform committed to bringing science-backed benefits to all and reframing the psychedelic conversation. This comes as Representative Earl Blumenauer recently circulated an open letter to his colleagues in Congress, urging them to join him in petitioning the DEA to permit terminally ill patients to use psilocybin as part of their treatment without fear of being federally prosecuted. Although the DEA has remained steadfast in…

Continue Reading

WednesdayFeb 09, 2022 12:26 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted US Patent Covering Lead Proprietary Compound for Treatment of Anxiety Disorders

Cybin (NEO: CYBN) (NYSE American: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, has been granted U.S. patent 11,242,318 to the company’s investigational deuterated dimethyltryptamine (“DMT”) compound CYB004. The patent, granted by the U.S. Patent and Trademark Office, strengthens the proprietary position of Cybin’s CYB004 as a deuterated DMT compound until 2041, covers composition of matter and protects the CYB004 drug substance as a putative new chemical entity. CYB004 is Cybin’s lead investigational proprietary DMT compound and in studies has shown potential efficacy at lower doses while also increasing the duration of drug effect providing a therapeutic profile that may…

Continue Reading

TuesdayFeb 08, 2022 3:34 pm

PsychedelicNewsBreaks – Microdose Psychedelic Insights Builds on IBN Partnership

Microdose Psychedelic Insights, a cutting-edge media company focused on promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of modern medicine, is building on its collaboration with InvestorBrandNetwork (“IBN”). IBN is a multifaceted financial news and publishing company. IBN will be supporting Microdose Psychedelic Insights throughout this year. A well-established leader within the psychedelic industry, Microdose is focused on providing educational insight to support the industry by distributing compelling sector content, financial analysis and engaging events. Microdose worked with IBN on its 2021 conference and looks forward to working with IBN as its official…

Continue Reading

TuesdayFeb 08, 2022 1:37 pm

PsychedelicNewsBreaks – Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Exclusive Dealer Identified as Supplier for Health Canada’s Special Access Program

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology company aiming to transform the treatment of mental health and addiction disorders. The company today announced that Health Canada has included the dealer’s license Mydecine operates under as a supplier for the Special Access Program (“SAP”), which allows health care providers to request specific drugs for approved patients who have not responded to other treatment options. Available to Mydecine through its exclusive agreement with Applied Pharmaceutical Innovation (“API”), the licensed dealer facility contains a unique research and development infrastructure as well as a manufacturing facility in Edmonton, Canada. With the…

Continue Reading

FridayFeb 04, 2022 1:58 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marks Major Accomplishments in 2021, Eyes ‘Truly Transformative’ 2022

Cybin (NYSE American: CYBN) (NEO: CYBN), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, accomplished a host of major milestones in 2021, proving it is on the right path to success. The company was awarded a notice of allowance by the U.S. Patent and Trademark Office for its CYB004 (deuterated psychedelic tryptamine) for the treatment of anxiety disorders and FDA approvals for its co-funded investigator-initiated phase 2 clinical trial. Cybin also confirmed a scientific advice meeting with the UK’s Medical and Healthcare Products Regulatory Agency regarding its lead candidate CYB003 for the treatment of major…

Continue Reading

ThursdayFeb 03, 2022 12:17 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Delic Labs to Present at Emerald Conference

Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), a leader in new medicines and treatments for a modern world, today announced that Dr. Markus Roggen, president and chief science officer for Delic Labs, will give a presentation on “Artificial Intelligence for Craft Cannabis Products” at the Emerald Conference. Dr. Roggen’s presentation is scheduled to begin at 12:45 p.m. PT on Monday, Feb. 28, 2022. “Focusing solely on extraction yields for cannabis extraction operations is an imprecise way to think about production,” said Dr. Roggen. “Quality of extract, cost of extraction and loss in post-processing should all be considered. Our laboratory…

Continue Reading

ThursdayFeb 03, 2022 11:29 am

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Strengthens Board with Appointment of Dr. Victoria Hale

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), a biotechnology company aiming to transform the treatment of mental health and addiction disorders, today announced the appointment of Dr. Victoria Hale to the company’s board of directors. A pharmaceutical scientist, executive and global health social entrepreneur, Dr. Hale currently serves as chair of the board of the Multidisciplinary Association for Psychedelic Studies (“MAPS”). A non-profit research and educational organization, MAPS works to raise awareness of psychedelics and help scientists design, fund and obtain regulatory approval of studies measuring the safety and effectiveness of psychedelics for therapeutic use. “We are thrilled to welcome…

Continue Reading

TuesdayFeb 01, 2022 12:11 pm

PsychedelicNewsBreaks – Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) at the Forefront of Research Investigating Psilocybin Compound for Smoking Cessation

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) is a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders. Mydecine has announced that, in preparation for its FDA pre-Investigational New Drug (“IND”) meeting on Feb. 28, the company has submitted a pre-IND briefing package to the U.S. Food and Drug Administration (“FDA”) for a clinical study evaluating MYCO-001 in a structured smoking cessation treatment program. Principal Investigator Dr. Matthew Johnson, Ph.D., professor of psychiatry and behavioral sciences at Johns Hopkins University, will lead the study that will assess the safety and efficacy of psilocybin-assisted…

Continue Reading

TuesdayFeb 01, 2022 11:10 am

PsychedelicNewsBreaks – Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (OTC: CMNDF) to Host Third Event in Psychedelics for Alcoholism Series

Clearmind Medicine (CSE: CMND) (FSE: CWY0) (OTC: CMNDF) a psychedelic drug company, has announced the speaker for the third webinar in its Psychedelics for Alcoholism series. The company has invited addiction specialist and world-renowned author Dr. Gabor Maté to talk on the effects of Alcohol Use Disorder, addition and trauma. The webinar will also include information about Clearmind's patented portfolio as an effective treatment for the disorder. A retired Vancouver physician and a member of the Order of Canada, Maté has written several books with his most recent book —  “The Myth of Normal: Trauma, Illness and Healing in a Toxic Culture” —…

Continue Reading